AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6769256 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment
Number of subjects: 0
Study 29775437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramill Motion 2 (CM)
Number of subjects: 60
Study 29775437 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirkonzahn (ZZ)
Number of subjects: 60
Study 29775437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cad4dent (CD)
Number of subjects: 60
Study 29775437 — intervention group
Group type: EXPERIMENTAL
Intervention: Weiland (WI)
Number of subjects: 60
Study 29775437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerec (CS)
Number of subjects: 60
Study 29049211 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg 24 hours preoperative administration (EPEA)
Number of subjects: 206
Study 29049211 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg 1 hour preoperative administration (PEA)
Number of subjects: 206
Study 29049211 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 400 mg 4 hours postoperative administration (POA)
Number of subjects: 206
Study 27056950 — intervention group
Group type: EXPERIMENTAL
Intervention: Pritelivir treatment (dosage not specified) for 28 days
Number of subjects: 87
Study 24612081 — intervention group
Group type: EXPERIMENTAL
Intervention: High-onion group (raw red onions: 2 × 40-50 g/day if overweight and 2 × 50-60 g/day if obese)
Number of subjects: 54
Study 24612081 — intervention group
Group type: COMPARATOR
Intervention: Low-onion group (raw red onions: 2 × 10-15 g/day)
Number of subjects: 54
Study 24612081 — intervention group
Group type: EXPERIMENTAL
Intervention: High-onion group
Number of subjects: 54
Study 24612081 — intervention group
Group type: COMPARATOR
Intervention: Low-onion group
Number of subjects: 54
Study 21961887 — intervention group
Group type: EXPERIMENTAL
Intervention: New Paracetamol pediatric suspension (PPS)
Number of subjects: 28
Study 21961887 — intervention group
Group type: COMPARATOR
Intervention: Children's panadol (CP)
Number of subjects: 28
Study 21961887 — intervention group
Group type: COMPARATOR
Intervention: Panodil baby & infant (PBI)
Number of subjects: 28
Study 19258948 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant platinum-based chemotherapy
Number of subjects: 448
Study 19258948 — intervention group
Group type: COMPARATOR
Intervention: Observation after surgical treatment
Number of subjects: 448
Study 17239142 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic navigation using a magnet‐tipped 0.014'' guidewire (Cronus guidewire) with a standard CS delivery sheath
Number of subjects: 50
Study 17239142 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic navigation using a magnet‐tipped 0.014'' guidewire (Cronus guidewire) with a 'bare‐wire' approach
Number of subjects: 50
Study 17239142 — intervention group
Group type: COMPARATOR
Intervention: Magnetic navigation
Number of subjects: 50
Study 15676171 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine 16 mg once-a-day
Number of subjects: 533
Study 15676171 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine 8 mg twice-a-day
Number of subjects: 533
Study 15676171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 533
Study 12092995 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest SpinBrush
Number of subjects: 38
Study 12092995 — intervention group
Group type: COMPARATOR
Intervention: Oral‐B Ultra Plaque Remover
Number of subjects: 38
Study 9830318 — intervention group
Group type: EXPERIMENTAL
Intervention: LARR1 group (induction with 4 days of etoposide and 4 days of high-dose ara-C)
Number of subjects: 24
Study 9830318 — intervention group
Group type: EXPERIMENTAL
Intervention: LARR2 group (induction with 4 days of etoposide plus 3 days of mitoxantrone)
Number of subjects: 24
Study 9830318 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 24
Study 7655964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse spray thrombolysis with 0.33 mg/ml rt‐PA injected as a bolus of 0.2 ml
Number of subjects: 18
Study 7655964 — intervention group
Group type: COMPARATOR
Intervention: Conventional thrombolysis with 0.05 mg/ml rt‐PA infused at a rate of 10 ml/h
Number of subjects: 18
Study 30931594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 9
Study 31030568 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 80
Study 31030568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31030568 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day (control group)
Number of subjects: 80
Study 28406125 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg OD for 24 weeks
Number of subjects: 153
Study 26707029 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal bilirubin levels
Number of subjects: 4228
Study 26707029 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bilirubin increase (per 1 mg/dL)
Number of subjects: 4228
Study 26707029 — intervention group
Group type: COMPARATOR
Intervention: Normal bilirubin levels
Number of subjects: 4228
Study 26707029 — intervention group
Group type: EXPERIMENTAL
Intervention: AST and ALT levels
Number of subjects: 4228
Study 25107530 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated HBV vaccination schedule (0, 1, and 2 months)
Number of subjects: 0
Study 25107530 — intervention group
Group type: COMPARATOR
Intervention: Standard HBV vaccination schedule (0, 1, and 6 months)
Number of subjects: 0
Study 25107530 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 0
Study 25107530 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor self-rated health score
Number of subjects: 0
Study 22207416 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 542
Study 22207416 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 542
Study 19821962 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental fluid (prescribed plus 10 mL/kg) for 5 days
Number of subjects: 64
Study 19821962 — intervention group
Group type: COMPARATOR
Intervention: Fluid volume prescribed
Number of subjects: 64
Study 19821962 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental fluid
Number of subjects: 64
Study 16777828 — intervention group
Group type: COMPARATOR
Intervention: Standard care (group 1)
Number of subjects: 352
Study 16777828 — intervention group
Group type: COMPARATOR
Intervention: Standard care plus assistance with scheduling follow-up (group 2)
Number of subjects: 352
Study 16777828 — intervention group
Group type: COMPARATOR
Intervention: Standard care plus assistance with scheduling follow-up and enrollment in a case management program (group 3)
Number of subjects: 352
Study 16777828 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including standard care)
Number of subjects: 352
Study 14993586 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber (glucomannan) 100 mg/kg body weight daily (max 5 g/day) for 4 weeks
Number of subjects: 31
Study 14993586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11282766 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 30
Study 11282766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11282766 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 30
Study 9227205 — intervention group
Group type: EXPERIMENTAL
Intervention: hEGF ophthalmic solution (30 micrograms/ml)
Number of subjects: 0
Study 9227205 — intervention group
Group type: EXPERIMENTAL
Intervention: hEGF ophthalmic solution (100 micrograms/ml)
Number of subjects: 0
Study 9227205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8260241 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen with 3M chemotherapy
Number of subjects: 94
Study 8260241 — intervention group
Group type: COMPARATOR
Intervention: 3M chemotherapy alone
Number of subjects: 94
Study 3631731 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater level of effort while breathing room air (25.0 ± 0.4 degrees C, 15.7 ± 0.2 mg H2O/L)
Number of subjects: 8
Study 3631731 — intervention group
Group type: COMPARATOR
Intervention: Lesser level of effort while breathing cold (0.0 ± 0.5 degrees C) and dry air (0 mg H2O/L)
Number of subjects: 8
Study 28980297 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote preconditioning (three cycles of 5 min inflation and 5 min deflation of a blood pressure cuff on the right arm)
Number of subjects: 120
Study 28980297 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 120
Study 27497511 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot MTA (DENTSPLY Tulsa Dental Specialties)
Number of subjects: 28
Study 27497511 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine (Septodont)
Number of subjects: 28
Study 27497511 — intervention group
Group type: COMPARATOR
Intervention: Negative control (dry sterile cotton pellet)
Number of subjects: 28
Study 27497511 — intervention group
Group type: COMPARATOR
Intervention: Positive control (blood‐moistened cotton pellet)
Number of subjects: 28
Study 24834924 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study 24834924 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 23921215 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2305
Study 20080017 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg or 8 mg in adults; 0.15 mg/kg in children
Number of subjects: 457
Study 20080017 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 457
Study 20080017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg in adults
Number of subjects: 457
Study 19214743 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront zoledronic acid 4 mg every 6 months
Number of subjects: 558
Study 19214743 — intervention group
Group type: COMPARATOR
Intervention: Delayed zoledronic acid 4 mg every 6 months (only given if post-baseline BMD T score < -2.0 or fracture)
Number of subjects: 558
Study 19214743 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront zoledronic acid
Number of subjects: 558
Study 19214743 — intervention group
Group type: COMPARATOR
Intervention: Delayed zoledronic acid
Number of subjects: 558
Study 15918823 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 100
Study 15918823 — intervention group
Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 100
Study 15918823 — intervention group
Group type: COMPARATOR
Intervention: Oxford position
Number of subjects: 100
Study 12586255 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg plus lovastatin (10, 20, or 40 mg)
Number of subjects: 548
Study 12586255 — intervention group
Group type: COMPARATOR
Intervention: lovastatin (10, 20, or 40 mg)
Number of subjects: 548
Study 12586255 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 548
Study 10589275 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment
Number of subjects: 0
Study 10589275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8998877 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest bone graft
Number of subjects: 55
Study 8998877 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized bone graft
Number of subjects: 55
Study 1662877 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 300 mg or 600 mg b.i.d.
Number of subjects: 584
Study 1662877 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg or 750 mg b.i.d.
Number of subjects: 584
Study 6789358 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine at doses of 0.75‐1.5 mg daily
Number of subjects: 30
Study 6789358 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐methyldopa at doses of 750‐1,500 mg daily
Number of subjects: 30
Study 6789358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31301123 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation over the left M1 for 10 minutes
Number of subjects: 32
Study 31301123 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS stimulation over the left M1 for 20 minutes
Number of subjects: 32
Study 30430971 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 0
Study 27184690 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant subcutaneous liraglutide 1.2 mg and insulin
Number of subjects: 15
Study 27184690 — intervention group
Group type: COMPARATOR
Intervention: Insulin monotherapy
Number of subjects: 15
Study 24738981 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide + formoterol
Number of subjects: 297
Study 24738981 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide + montelukast
Number of subjects: 297
Study 24738981 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide + doxofylline
Number of subjects: 297
Study 24738981 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide + tiotropium
Number of subjects: 297
Study 22344322 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivalent polyclonal antibody preparation (PAP) at 10 mL·d(‐1)
Number of subjects: 96
Study 22344322 — intervention group
Group type: COMPARATOR
Intervention: Monensin (MON) at 300 mg·d(‐1)
Number of subjects: 96
Study 22344322 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivalent polyclonal antibody preparation (PAP)
Number of subjects: 96
Study 22344322 — intervention group
Group type: COMPARATOR
Intervention: Monensin (MON)
Number of subjects: 96
Study 22344322 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossbred yearling bulls (TC and CC)
Number of subjects: 96
Study 22344322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nellore yearling bulls (NE)
Number of subjects: 96
Study 20956904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine 75 micrograms
Number of subjects: 90
Study 20956904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine 150 micrograms
Number of subjects: 90
Study 20956904 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 90
Study 17701671 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of intramuscular ergometrine
Number of subjects: 510
Study 17701671 — intervention group
Group type: COMPARATOR
Intervention: 10 IU of intravenous oxytocin
Number of subjects: 510
Study 15651178 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC)
Number of subjects: 0
Study 15651178 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 0
Study 15651178 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0
Study 15651178 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 0
Study 11678838 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Learning (CAL) programme
Number of subjects: 185
Study 11678838 — intervention group
Group type: COMPARATOR
Intervention: Conventional lectures
Number of subjects: 185
Study 9131944 — intervention group
Group type: EXPERIMENTAL
Intervention: SeBA-GEN
Number of subjects: 100
Study 9131944 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBOTTBASE
Number of subjects: 100
Study 9131944 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SeBA-GEN and ABBOTTBASE
Number of subjects: 100
Study 21207910 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchored Instruction (AI)
Number of subjects: 81
Study 2975148 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral rectus sheath block
Number of subjects: 60
Study 2975148 — intervention group
Group type: COMPARATOR
Intervention: Standardised general anaesthetic technique alone
Number of subjects: 60
Study 29538258 — intervention group
Group type: EXPERIMENTAL
Intervention: ADXS11-001
Number of subjects: 109
Study 29538258 — intervention group
Group type: EXPERIMENTAL
Intervention: ADXS11-001 + cisplatin
Number of subjects: 109
Study 27681753 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab + RT
Number of subjects: 22
Study 24534638 — intervention group
Group type: EXPERIMENTAL
Intervention: rEVAR (endovascular repair) before the trial
Number of subjects: 169
Study 24534638 — intervention group
Group type: EXPERIMENTAL
Intervention: rEVAR (endovascular repair) during the trial
Number of subjects: 169
Study 24534638 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality before and during the trial
Number of subjects: 169
Study 24534638 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 169
Study 24534638 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated during the trial
Number of subjects: 169
Study 24534638 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised patients
Number of subjects: 169
Study 22385032 — intervention group
Group type: EXPERIMENTAL
Intervention: Over the counter soft-solid antiperspirant
Number of subjects: 0
Study 22385032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22385032 — intervention group
Group type: COMPARATOR
Intervention: Prescription aluminum chloride (6.5%) antiperspirant
Number of subjects: 0
Study 20491723 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation Enhancement Treatment (MET)
Number of subjects: 1726
Study 20491723 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 1726
Study 18946896 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 337
Study 18946896 — intervention group
Group type: COMPARATOR
Intervention: Ioversol
Number of subjects: 337
Study 18946896 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (diabetic subset)
Number of subjects: 337
Study 18946896 — intervention group
Group type: COMPARATOR
Intervention: Ioversol (diabetic subset)
Number of subjects: 337
Study 16351808 — intervention group
Group type: EXPERIMENTAL
Intervention: CF/5‐FU + Taxol
Number of subjects: 180
Study 16351808 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol + OXA
Number of subjects: 180
Study 16351808 — intervention group
Group type: COMPARATOR
Intervention: CF/5‐FU + DDP (control)
Number of subjects: 180
Study 12430111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375%
Number of subjects: 51
Study 12430111 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 0.5%
Number of subjects: 51
Study 10553503 — intervention group
Group type: EXPERIMENTAL
Intervention: DQB1*02‐DQA1*0501/DQB1*0302‐DQA1*0301 heterozygotes
Number of subjects: 420
Study 10553503 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous presence of both DRB1*03 and DQB1*0302
Number of subjects: 420
Study 10553503 — intervention group
Group type: COMPARATOR
Intervention: DQB1*0302 among DRB1*04 patients
Number of subjects: 420
Study 10553503 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1*03 among DQA1*0501 patients
Number of subjects: 420
Study 10553503 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1*03 among DQB1*02 patients
Number of subjects: 420
Study 10553503 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1*03‐DQA1*0501‐DQB1*02 haplotype
Number of subjects: 420
Study 10553503 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1*04‐DQA1*0301‐DQB1*0302 haplotype
Number of subjects: 420
Study 10553503 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1*0401
Number of subjects: 420
Study 8691924 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 100
Study 8691924 — intervention group
Group type: EXPERIMENTAL
Intervention: Second BCG
Number of subjects: 100
Study 8691924 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG plus killed M leprae
Number of subjects: 100
Study 8691924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1721129 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous cardiac pacing (TCP)
Number of subjects: 51
Study 7036282 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with levamisole
Number of subjects: 50
Study 7036282 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 50
Study 7036282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without levamisole)
Number of subjects: 50
Study 7036282 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 50
Study 31852125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extracts (GBEs) plus Shenmayizhi decoction (SMYZD) granule
Number of subjects: 196
Study 31852125 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba extracts (GBEs) plus Shenmayizhi mimetic granule
Number of subjects: 196
Study 29037649 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique (MET)
Number of subjects: 64
Study 29037649 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Release Technique (ART)
Number of subjects: 64
Study 26266414 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis (CD2)-containing lozenges, 4 tablets/day for 14 days
Number of subjects: 20
Study 26266414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24866253 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Narrative Exposure Therapy (brief NET), 3 sessions, conducted individually, in Arabic
Number of subjects: 63
Study 24866253 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 63
Study 21617197 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose cyclosporine (Stand-CsA)
Number of subjects: 1645
Study 21617197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine (Low-CsA)
Number of subjects: 1645
Study 21617197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sirolimus (Low-SRL)
Number of subjects: 1645
Study 21617197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (Low-Tac)
Number of subjects: 1645
Study 21617197 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose cyclosporine (Stand-CsA) and Low-dose cyclosporine (Low-CsA)
Number of subjects: 1645
Study 21617197 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 1645
Study 19020496 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (as a prototypical irreversible inhibitor of CYP3A)
Number of subjects: 30
Study 17164159 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 37